200 related articles for article (PubMed ID: 11896595)
21. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
22. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.
Hassan NM; Tada M; Hamada J; Kashiwazaki H; Kameyama T; Akhter R; Yamazaki Y; Yano M; Inoue N; Moriuchi T
Cancer Lett; 2008 Oct; 270(1):108-19. PubMed ID: 18555592
[TBL] [Abstract][Full Text] [Related]
23. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
[TBL] [Abstract][Full Text] [Related]
24. p53 transdominance but no gain of function in mouse brain tumor model.
Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
[TBL] [Abstract][Full Text] [Related]
25. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P
Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672
[TBL] [Abstract][Full Text] [Related]
26. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
27. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
28. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
29. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
30. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
33. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
[TBL] [Abstract][Full Text] [Related]
34. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
35. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
Tarunina M; Jenkins JR
Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
[TBL] [Abstract][Full Text] [Related]
36. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
[TBL] [Abstract][Full Text] [Related]
37. p53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells.
Schmieg FI; Simmons DT
Oncogene; 1993 Aug; 8(8):2043-50. PubMed ID: 8393158
[TBL] [Abstract][Full Text] [Related]
38. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
Zhang W; Shay JW; Deisseroth A
Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
[TBL] [Abstract][Full Text] [Related]
39. Transforming activity of mutant human p53 alleles.
Slingerland JM; Benchimol S
J Cell Physiol; 1991 Sep; 148(3):391-5. PubMed ID: 1918170
[TBL] [Abstract][Full Text] [Related]
40. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
Chang F; Syrjänen S; Kurvinen K; Syrjänen K
Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
